Tien-Li Lee - 10 Sep 2025 Form 4 Insider Report for Aardvark Therapeutics, Inc. (AARD)

Role
Chief Executive Officer, Director, 10%+ Owner
Signature
/s/ Samantha Eldredge, as Attorney-in-Fact
Issuer symbol
AARD
Transactions as of
10 Sep 2025
Transactions value $
$160,654
Form type
4
Filing time
12 Sep 2025, 20:28:02 UTC
Previous filing
29 Aug 2025
Next filing
16 Sep 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Lee Tien-Li Chief Executive Officer, Director, 10%+ Owner C/O AARDVARK THERAPEUTICS, INC., 4370 LA JOLLA VILLAGE DRIVE, SUITE 1050, SAN DIEGO /s/ Samantha Eldredge, as Attorney-in-Fact 12 Sep 2025 0001940120

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction AARD Common Stock Purchase $71.2K +9K +0.59% $7.91 1.52M 10 Sep 2025 Direct F1
transaction AARD Common Stock Purchase $46.9K +6K +0.39% $7.82 1.53M 11 Sep 2025 Direct F2
transaction AARD Common Stock Purchase $42.5K +5K +0.33% $8.50 1.53M 12 Sep 2025 Direct F3
holding AARD Common Stock 1.47M 10 Sep 2025 By Spouse
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $7.84 to $7.95 per share, inclusive. The reporting person undertakes to provide Aardvark Therapeutics, Inc. ("Aardvark"), any security holder of Aardvark, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
F2 The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $7.8135 to $7.825 per share, inclusive. The reporting person undertakes to provide Aardvark Therapeutics, Inc. ("Aardvark"), any security holder of Aardvark, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
F3 The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $8.4199 to $8.69 per share, inclusive. The reporting person undertakes to provide Aardvark Therapeutics, Inc. ("Aardvark"), any security holder of Aardvark, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.